Our study provided proof-of-principle data supporting that HDACi may be a potential therapeutic strategy to stimulate ITPR3 transcription through SMARCA2 reactivation and sensitize SMARCA4/2-deficient cancers to chemotherapy. The gene discussed is ITPR3; the disease is cancer.